Thursday November 26 2009 | Biotechnology feed | All feeds

BioPortfolio Biotechnology Pharmaceutical Healthcare Medical Life Science Drug Discovery Disease

Takeda Pharmaceutical Company Limited

Thumbshot of's website
http://www.takeda.com

FDA Continues Review of Takeda?s New Drug Application for Alogliptin (SYR-322), a DPP-4 Agent for Type 2 Diabetes

Friday 10th of October 2008 3:00

BioPortfolio no longer holds the full text of this article, it is however likley to be available via the below links:

    Google Custom Search
    Browse other news from this organisation: Takeda Pharmaceutical Company Limited

    Related Web-Links

    (If any, Generated Automatically)
    Google Custom Search

    Source PR Newswire

    PR Newswire Logo
    www.prnewswire.co.uk

    Browse news from 2008

    Download PDF PDF Version
     

    Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner.

    All rights reserved. All other trademarks recognized.
    Copyright 1997-2009 - BioPortfolio Limited.